Dr. Lisa Jennings, a clinical professor in the College of Medicine at the University of Tennessee Health Science Center, is the founder of CirQuest Labs and co-founder of Ariste Medical. CirQuest Labs is a multi-service specialty laboratory and direct marketer of clinical trial logistics to the pharmaceutical and medical device industries. She explains her endeavor… Read More
The UT Institute for Research, Innovation, Synergy and Health Equity at the University of Tennessee Health Science Center (UTHSC) has announced the latest round of grant recipients from its Pilot Translational and Clinical Studies (PTCS) Program. Six UTHSC researchers were chosen from a field of 28 submissions.
Lebron Cooper, MD, has been named chair for the Department of Anesthesiology at UTHSC. An alumnus of the UTHSC College of Medicine, he will begin his new role on Sept. 28.
… the University of Tennessee Health Science Center (UTHSC) and Le Bonheur Children’s Hospital opened a Healthy Lifestyles Clinic as part of their joint Pediatric Obesity Program under the direction of Joan Han, MD, a Harvard-educated endocrinologist and former U.S. Public Health Service officer.
page 12: “Treatment of Cancer Patients in Memphis — Now Staying in Memphis” by Martin D. Fleming, MD, Division Chief, Division of Surgical Oncology, UTHSC cover photo: David Shibata, MD, FACS, FASCRS, Scheinberg Endowed Chair of Surgery for the UTHSC Department of Surgery
The study, led by Csaba P. Kovesdy, MD, of the Memphis VA Medical Center and the University of Tennessee Health Science Center in Memphis, included 2,525,525 white and 547,441 black patients with normal kidney function receiving care in the VA healthcare system.
One of the most exciting novel developments is an oral vaccine developed not for people, but for mice, invented by Maria Gomes-Solecki at the University of Tennessee Health Science Center . . . The idea is that by vaccinating them, we can control Lyme disease in these rodents and the ticks, and subsequently reduce transmission… Read More
The vaccine was developed by Dr. James Dale at the University of Tennessee Health Science Center and is being commercialized by PREVENT and Vaxent. The Phase I trial was announced in August.
